DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai, based in Woodcliff Lake, NJ, USA, for the production of sterile products.
The agreement covers the production of eribulin mesylate as well as other developmental drugs.
DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013. L
No financial details were disclosed.
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
Novo Nordisk recently announced changes to its executive leadership and Board of Directors.
Valerie Diele-Braun resigned from her position as CEO and member of the Executive Board of IMCD at the end of April for personal reasons.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
